Sign In
Buy HRTX
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
11:45am, Tuesday, 12'th Nov 2024
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ir
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11:00am, Tuesday, 12'th Nov 2024
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare wi
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
10:11am, Tuesday, 12'th Nov 2024
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
07:55am, Tuesday, 12'th Nov 2024
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine and meloxicam) extended-release solutio
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
10:21am, Thursday, 07'th Nov 2024
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
05:00pm, Monday, 04'th Nov 2024
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors.
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
04:05pm, Tuesday, 29'th Oct 2024
SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a con
SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
08:00am, Wednesday, 25'th Sep 2024
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewsw
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
08:00am, Tuesday, 03'rd Sep 2024
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
08:31pm, Tuesday, 06'th Aug 2024
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Tuesday, 06'th Aug 2024
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
04:05pm, Tuesday, 06'th Aug 2024
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRE
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
04:05pm, Tuesday, 30'th Jul 2024
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webca
SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and
